[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338166-105":59,"doc-detail-338166-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gut-microbiota-and-clinical-response-to-immune-checkpoint-inhibitor-therapy-in-patients-with-advanced-cancer-research-findings","Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer - Research findings","","Background: No well-accepted consensus exists on how gut microbiota relates to immune checkpoint inhibitor (ICI) response in advanced cancer. Methods: Fecal samples were collected before ICI therapy; gut microbiota was profiled using 16S rRNA sequencing, including α-diversity analyses and comparison with healthy controls. Pre-treatment serum cytokines were assessed via cytokine array. Results: Among 74 patients, clinical benefit occurred in 47.3%, with α-diversity not differing between groups, but normal-range α-diversity predicted longer overall survival (18.9 vs 8.2 months). Prevotella copri and Faecalibacterium prausnitzii correlated with favorable outcomes, and IL-18 was lower in benefiters. Conclusions: Gut microbiota α-diversity correlates positively with prolonged overall survival after ICI therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gut-microbiota-and-clinical-response-to-immune-checkpoint-inhibitor-therapy-in-patients-with-advanced-cancer-research-findings/338166/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gut-microbiota-and-clinical-response-to-immune-checkpoint-inhibitor-therapy-in-patients-with-advanced-cancer-research-findings/338166.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was gut microbiota assessed before immune checkpoint inhibitor treatment?","Question",{"text":112,"@type":113},"Fecal samples were collected before ICI therapy and gut microbiota was analyzed using 16S ribosomal RNA sequencing, including evaluation of α-diversity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Did α-diversity differ between patients with clinical benefit and those without?",{"text":117,"@type":113},"No significant difference in α-diversity was found between benefiter and non-benefiter groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What gut microbiota and serum biomarkers were linked to favorable outcomes?",{"text":121,"@type":113},"Patients whose α-diversity fell within the healthy-control range had longer overall survival, and Prevotella copri and Faecalibacterium prausnitzii were associated with favorable outcomes. Pre-treatment serum IL-18 was also significantly lower in benefiters.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338166,1790142252,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Biomedical Journal 47 (2024) 100698  \nContents lists available at ScienceDirect Biomedical Journal  \njournal [homepage:](homepage: www.elsevier.com/locate/bj)[ www.elsevier.com/locate/bj](homepage: www.elsevier.com/locate/bj)  \n| Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer |  |  | |\n| --- | --- | --- | --- |\n| John Wen-Cheng Chang a,b, Jia-Juan Hsieh a, Chih-Yu Tsaia, Horng-Yih Chiuc, Yu-Feng Lin b,d, Chiao-En Wu a,b, Yung-Chi Shena, Ming-Mo Houa,b, Chieh-Ying Chang a, Jian-An Chena, Chyi-Liang Chene,f, Cheng-Tang Chiug,h, Yuan-Ming Yeh h,i,j,*, Cheng-Hsun Chiue,h,k,**\u003Cbr>a Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan\u003Cbr>b Immuno-Oncology Center of Excellence, Chang Gung Memorial Hospital, Taoyuan, Taiwan c School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan d Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan\u003Cbr>e Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan\u003Cbr>f Department of Microbiology and Immunology, Chang Gung University College of Medicine, Taoyuan, Taiwan\u003Cbr>g Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan h Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan\u003Cbr>i Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Taoyuan, Taiwan j Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Taoyuan, Taiwan\u003Cbr>k Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Immune checkpoint inhibitors Clinical response Gut microbiota |  | Background: There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer.\u003Cbr>Methods: Fecal samples were collected before ICI treatment. Gut microbiota was analyzed using 16 S ribosomal RNA sequencing. We investigated the relationship between the α-diversity of fecal microbiota and patients’clinical outcomes. Microbiota profiles from patients and healthy controls were determined. Pre-treatment serum was examined by cytokine array.\u003Cbr>Results: We analyzed 74 patients, including 42 with melanoma, 8 with kidney cancer, 13 with lung cancer, and 11 with other cancers. Combination therapy of anti-PD1 and anti-CTLA-4 was used in 14 patients, and monotherapy in the rest. Clinical benefit was observed in 35 (47.3 %) cases, including 2 complete responses, 16 partial responses, and 17 stable diseases according to RECIST criteria. No significant difference in α-diversity was found between the benefiter and non-benefiter groups. However, patients with α-diversity within the range of our healthy control had a significantly longer median overall survival (18.9 months), compared to the abnormal group (8.2 months) (p = 0.041, hazard ratio = 0.546) for all patients. The microbiota composition of the benefiters was similar to that of healthy individuals. Furthermore, specific bacteria, such as Prevotella copri and Faecalibacterium prausnitzii, were associated with a favorable outcome. We also observed that serum IL-18 before treatment was significantly lower in the benefiters, compared to non-benefiters.\u003Cbr>Conclusions: The α-diversity of gut microbiota is positively correlated with more prolonged overall survival in cancer patients following ICI therapy. |  |\n\nPeer review under responsibility of Chang Gung University.  \n* Corresponding author. Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, No.5, Fuxing St., Guishan Dist., Taoyuan City 333, Taiwan.  \n** Corresponding author. Division of Pediatric Infectious Diseas","cbCaiqGyOnLUQlEn","https://ap.wps.com/l/cbCaiqGyOnLUQlEn","pdf",3041959,"English","# Background\n# Methods\n# Results\n# Conclusions\n# At a glance of commentary\n## Scientific background on the subject\n## What this study adds to the field","[{\"question\":\"How was gut microbiota assessed before immune checkpoint inhibitor treatment?\",\"answer\":\"Fecal samples were collected before ICI therapy and gut microbiota was analyzed using 16S ribosomal RNA sequencing, including evaluation of α-diversity.\"},{\"question\":\"Did α-diversity differ between patients with clinical benefit and those without?\",\"answer\":\"No significant difference in α-diversity was found between benefiter and non-benefiter groups.\"},{\"question\":\"What gut microbiota and serum biomarkers were linked to favorable outcomes?\",\"answer\":\"Patients whose α-diversity fell within the healthy-control range had longer overall survival, and Prevotella copri and Faecalibacterium prausnitzii were associated with favorable outcomes. Pre-treatment serum IL-18 was also significantly lower in benefiters.\"}]","Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer - Research findings | PDF",1790022314,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d677d717bdbe283d18422dea584c6858.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e827ee01bf7ed0bb12d3820360580b99.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e828831727dbb4f7e177ef276f75e295.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b8c0e0486e29628ab3c54e2e657d25c.webp",980,1306]